The findings provide a new and important theoretical basis for the pathogenesis of HBV-GN (i.e., the direct HBV infection of renal tissue cells) and open the door to investigate blocking NTCP as a new target for HBV-GN therapy. The gene discussed is SLC10A1; the disease is ganglioneuroma.